A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer

摘要

Aim: We investigated the combination of irinotecan and panitumumab as a 3-weekly schedule in patients with wild-type KRAS metastatic colorectal cancer, who had progressed after standard chemotherapy. Material & methods: Patients received concomitant irinotecan (350 mg/m2) and panitumumab (9 mg/kg) once every 3 weeks. The primary end point was response rate. Secondary end points included progression-free survival (PFS), overall survival (OS) and translational research. Results: Inclusion was stopped early owing to lack of efficacy (n = 31). The response rate was 16%, median PFS and OS was 2.0 months (95% Cl: 1.9-4.0) and 7.8 months (95% Cl: 4.6-8.8), respectively. The most commonly encountered adverse event was skin rash (84% any grade). Pretreatment cell-free DNA levels were significantly related to disease control (p = 0.04), PFS (p = 0.04) and OS (p = 0.002), respectively. Conclusion: The present treatment regimen was less effective than expected and is not recommended. The clinical importance of cell-free DNA deserves further research.